Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,999.00
Bid: 1,997.00
Ask: 1,998.00
Change: 34.00 (1.73%)
Spread: 1.00 (0.05%)
Open: 1,991.00
High: 2,028.00
Low: 1,983.00
Prev. Close: 1,965.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Construction, pharma, gold miners seen as Europe's top Trump trades

Wed, 09th Nov 2016 14:03

(Adds extra companies)

LONDON, Nov 9 (Reuters) - Global markets reacted onWednesday with concern to Donald Trump's surprise victory in theU.S. presidential election, but construction, pharma and goldmining stocks emerged as big winners in the European tradingsession.

Gains in those three sectors helped pull European stocks off their early lows that had followed a slump in WallStreet futures. The European index had been expected to open asmuch as 4 percent lower on the election outcome but in the endwas only down about two percent at the outset.

At 1358 GMT the index was down 0.4 percent.

Healthcare stocks were the biggest outperformers, up2.8 percent, followed by basic resources, up 2.4percent, and construction and materials, up 1.2 percent.

The STOXX 600 was down 0.6 percent by midday trading.

Markets had expected Democrat contender Hillary Clinton towin the election rather than Trump, a political outsider with noexperience of public office. Growth-sensitive shares such asautos, financial and travel shares all came under pressure fromthe uncertainty over what a Trump presidency will look like.

Stocks with substantial revenue exposure to the Mexicanpeso, and some with U.S. exposure, were also hit as bothcurrencies have come under pressure.

However, stocks of companies with American exposure thatstand to benefit from Trump's spending plans are seeing a lift.And those that have costs in pesos, rather than derive revenuesfrom Mexico, are also "winners" from the election result.

TRUMP WINNERS

* FRESNILLO - Gold miners are safe-haven playswhich benefit in times of uncertainty. Fresnillo is in additiona Mexico-based, London-listed, dollar-earning company. As suchthe 13 percent slide in the peso provided another lift toFresnillo. Its shares were up 9 percent on Wednesday, the topSTOXX 600 gainer.

* BAE SYSTEMS - Trump's non-committal stance onsupporting NATO allies might prompt increased defence spendingin Europe. Societe Generale picked out BAE Systems as a stockthat could benefit, and say that the sector is at a 5 percentdiscount to the European market and a 20 percent discount to theU.S. defence sector. The stock rose over 3 percent to anall-time high.

* HIKMA, BB BIOTECH - Pharmaceuticals hadbeen inversely correlated with the chances of a Clintonpresidency, as she has proposed higher regulation of pricing inthe sector. Hikma and BB Biotech were both up over 7 percentafter Trump won. Barclays had picked out Hikma as a beneficiaryif Trump won ahead of the election, deriving around half of itsrevenues from the United States. Shire and Novo Nordisk also rallied strongly.

* CRH - The construction firm hit a nine-year highon Wednesday as Trump has pledged to boost infrastructurespending. Trump's acceptance speech, which struck a conciliatorynote and avoided reference to controversial policies mentionedon the campaign trail, reiterated his commitment to increasedinfrastructure spending. CRH derives 50 percent of its revenuesfrom the United States.

* ASHTEAD - Ashtead is identified by Deutsche Bankas the European firm with the highest exposure to increasedinfrastructure spending in the United States, with 84 percent ofits revenues derived there.

* HEIDELBERGCEMENT - Heidelbergcement has said itsees benefits in the medium term from a Trump presidency, eventhough investment might be delayed in the short run. It isexpected to benefit from increased infrastructure spending, andwas up 2.4 percent.

TRUMP LOSERS

* BBVA - BBVA is identified by Credit Suisse andSociete Generale as the European bank most exposed to Mexico,from where it derives around 30 percent of its revenues. Thestock would suffer if Trump got into power and scrapped theNorth American Free Trade Agreement, as he has pledged to do.BBVA was down 8.8 percent, its biggest one-day fall since theBrexit vote.

* TATE AND LYLE - Tate & Lyle fell 9 percent, andhas 10 percent exposure to the peso. BNP Paribas downgraded thestock to "underperform" on Wednesday, saying that its Mexicanexposure would weigh on sentiment and profits.

* VESTAS WIND - Renewable energy firms took apounding on concern that President-Elect Trump will cut supportto the sector as he looks to promote coal and other fossilfuels. Vestas derives 40 percent of its revenue from the UnitedStates, per Barclays, and was down 7.2 percent.

* NESTE - Concerns over Trump's approach to theenergy sector also hit Neste. The Finnish renewable diesel makerfell 6.2 percent as the dollar weakened, with concern mountingthat Trump would tweak a tax break for biofuels.

* HEINEKEN, AB INBEV - Brewers Heinekenand AB InBev have substantial exposure to emerging markets likeMexico. Even though food and beverage stocks are seen broadly asdefensive, these two stocks were down over 4 percent.

* DSV - Cantor Fitzgerald highlight transport andlogistics stocks as being at risk should a Trump presidencyresult in a slowdown in global trade. "The risk for the largerglobal freight forwarding operators... is that trade is impededwith new barriers, particularly with China." Denmark's DSV wasdown 3 percent. (Reporting by Alistair Smout; Editing by Gareth Jones)

More News
4 Nov 2021 09:03

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

Read more
4 Nov 2021 07:58

Hikma reports solid trading in year to date

(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.

Read more
1 Nov 2021 13:52

Citi sees room for upside surprise on sales at Hikma Pharmaceuticals

(Sharecast News) - Analysts at Citi reiterated their 'buy' stance for shares of Hikma Pharmaceuticals ahead of the company's trading statement due out later in the same week.

Read more
28 Oct 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
20 Oct 2021 09:51

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

Read more
27 Sep 2021 12:14

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

Read more
27 Sep 2021 09:31

LONDON BROKER RATINGS: Upgrades for Ferrexpo, Go-Ahead and Old Mutual

LONDON BROKER RATINGS: Upgrades for Ferrexpo, Go-Ahead and Old Mutual

Read more
27 Sep 2021 09:28

UPDATE 2-Energy stocks, banks lift FTSE 100; Rolls-Royce top performer

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Rolls-Royce jumps on sales of Spain-based ITP, U.S. Air Force contract* Energy stocks track crude oil prices higher* Hikma Pharma gains o...

Read more
27 Sep 2021 08:50

LONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win

LONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win

Read more
27 Sep 2021 08:16

TOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million

TOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million

Read more
27 Sep 2021 07:49

LONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract

LONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract

Read more
27 Sep 2021 07:05

Hikma buys Custopharm for $375m

(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.

Read more
27 Sep 2021 07:05

Hikma buys Custopharm for $375m

(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.

Read more
13 Sep 2021 16:09

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
2 Sep 2021 09:38

LONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC

LONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.